Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vera Therapeutics, Inc.

22.65
-0.6400-2.75%
Post-market: 22.650.00000.00%19:15 EDT
Volume:2.68M
Turnover:61.08M
Market Cap:1.44B
PE:-7.55
High:23.38
Open:23.19
Low:22.28
Close:23.29
Loading ...

Vera Therapeutics' Q1 Net Loss Widens

MT Newswires Live
·
06 May

Earnings Flash (VERA) Vera Therapeutics Posts Q1 Net Loss $0.81 a Share, vs. FactSet Est of $0.75 Loss

MT Newswires Live
·
06 May

Vera Therapeutics Q1 EPS $(0.81) Misses $(0.73) Estimate

Benzinga
·
06 May

BRIEF-Vera Therapeutics Q1 EPS USD -0.81 Vs. IBES Estimate USD -0.74

Reuters
·
06 May

Press Release: Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Dow Jones
·
06 May

Vera Therapeutics Coverage Assumed by HC Wainwright & Co. at Buy

Dow Jones
·
06 May

Analysts Offer Insights on Healthcare Companies: Baxter International (BAX) and Vera Therapeutics (VERA)

TIPRANKS
·
05 May

Vera Therapeutics Inc : H.c. Wainwright Assumes Coverage With Buy Rating; Price Target $75

THOMSON REUTERS
·
05 May

Vera Therapeutics assumed with a Buy at H.C. Wainwright

TIPRANKS
·
05 May

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
10 Apr

Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch

Benzinga
·
10 Apr

Guggenheim Reaffirms Their Buy Rating on Vera Therapeutics (VERA)

TIPRANKS
·
07 Apr

Positive Outlook for Vera Therapeutics: Buy Rating on Atacicept’s Potential in IgA Nephropathy

TIPRANKS
·
03 Apr

Vera Therapeutics completes enrollment in ORIGIN Phase 3 trial for atacicept

TIPRANKS
·
03 Apr

Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN

GlobeNewswire
·
03 Apr

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
12 Mar

Stock Track | Vera Therapeutics Soars 5.21% on Buy Rating and Price Target Increase from TD Cowen

Stock Track
·
06 Mar

Vera Therapeutics (VERA) Gets a Buy from TD Cowen

TIPRANKS
·
05 Mar

Vera Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
05 Mar

Vera Therapeutics price target lowered to $71 from $77 at JPMorgan

TIPRANKS
·
04 Mar